Abstract
Nonalcoholic fatty liver disease (NAFLD) is a common disease of chronic liver diseases. Peroxisome proliferator-activated receptor α (PPARα) has been implicated to play important roles in the development of the disease. Beyond its effects on lipid metabolisms, PPARα activation in the vascular system has emerged as an attractive therapeutic potential for NAFLD, although its actions in the microcirculatory system are not fully understood. In this study, we investigated the effects of fenofibrate, a PPARα synthetic agonist, on hepatic microcirculation in a high-fat diet (HFD)-induced fatty liver in mice. In vivo imaging analysis revealed the adverse effects of HFD on hepatic vasculature with narrowing of hepatic sinusoids and hepatic microcirculatory perfusion. Oxygen tension was significantly decreased in portal venules, while NADH autofluorescence in hepatocytes was greatly elevated. Fenofibrate treatment remarkably improved microvascular patency, tissue oxygenation and redox states in the affected liver. These results suggest beneficial roles of PPARα activated by fenofibrate on the regulation of both lipid metabolisms and microvascular environments of oxygen metabolism in HFD-induced fatty liver.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Irukayama-Tomobe Y, Miyauchi T, Sakai S et al. (2004) Endothelin-1-induced cardiac hypertrophy is inhibited by activation of peroxisome proliferator-activated receptor-alpha partly via blockade of c-Jun NH2-terminal kinase pathway. Circulation 109(7):904–910.
Lee SS, Pineau T, Drago J et al. (1995) Targeted disruption of the alpha isoform of the peroxisome proliferator-activated receptor gene in mice results in abolishment of the pleiotropic effects of peroxisome proliferators. Mol Cell Biol 15:3012–3022.
Lefebvre P, Chinetti G, Fruchart JC et al. (2006) Sorting out the roles of PPAR alpha in energy metabolism and vascular homeostasis. J Clin Invest 116(3):571–580.
Murakami H, Murakami R, Kambe F et al. (2006) Fenofibrate activates AMPK and increases eNOS phosphorylation in HUVEC. Biochem Biophys Res Commun 341(4):973–978.
Postic C, Girard J (2008) Contribution of de novo fatty acid synthesis to hepatic steatosis and insulin resistance: lessons from genetically engineered mice. J Clin Invest 118(3):829–838.
Reddy JK, Rao MS (2006) Lipid metabolism and liver inflammation. II. Fatty liver disease and fatty acid oxidation. Am J Physiol Gastrointest Liver Physiol 290(5):G852–G858.
Seifalian AM, Piasecki C, Agarwal A et al. (1999) The effect of graded steatosis on flow in the hepatic parenchymal microcirculation. Transplantation 68(6):780–784.
Tsukada K, Sekizuka E, Oshio C et al. (2004) Red blood cell velocity and oxygen tension measurement in cerebral microvessels by double-wavelength photoexcitation. J Appl Physiol 96(4):1561–1568.
Acknowledgments
This work was supported by Japan Society for the Promotion of Science Grant-in-Aid for Creative Scientific Research 17GS0419 and by CREST, JST.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2010 Springer Science+Business Media, LLC
About this paper
Cite this paper
Kondo, K. et al. (2010). Fenofibrate, a Peroxisome Proliferator-Activated Receptor α Agonist, Improves Hepatic Microcirculatory Patency and Oxygen Availability in a High-Fat-Diet-Induced Fatty Liver in Mice. In: Takahashi, E., Bruley, D. (eds) Oxygen Transport to Tissue XXXI. Advances in Experimental Medicine and Biology, vol 662. Springer, Boston, MA. https://doi.org/10.1007/978-1-4419-1241-1_10
Download citation
DOI: https://doi.org/10.1007/978-1-4419-1241-1_10
Published:
Publisher Name: Springer, Boston, MA
Print ISBN: 978-1-4419-1239-8
Online ISBN: 978-1-4419-1241-1
eBook Packages: Biomedical and Life SciencesBiomedical and Life Sciences (R0)